bullish
Celltrion Inc (068270 KS): Turning Bullish As Biosimilar Revenue Rebounds & US Launches Imminent
246 Views15 May 2023 17:37
SUMMARY
- Celltrion Inc (068270 KS) recorded double-digit revenue and operating profit growth in Q1. Biosimilars reported first-ever KRW400B+ quarterly revenue. Operating margin reached to 30.5% in 1Q23 from 24.3% in 1Q22.
- Remsima SC sales (27% of revenue) resumed at full scale and rebounded to KRW100B quarterly revenue after a gap of ~2.5 years, driven by increasing market share in EU.
- This year, Celltrion is expected to launch three products in the U.S.: Vegzelma (biosimilar bevacizumab), Yuflyma (biosimilar adalimumab), and a novel subcutaneous formulation of infliximab.
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Top Quartile
Tina Banerjee
Global Healthcare Analyst
Price Chart(Sign Up to Access)
- Alpha Generation Through Share Buybacks in Korea: June & July 202324 Jul 2023
- Celltrion (068270 KS): Humira Biosimilar Launch in US; Filed New Biosimilar Marketing Application04 Jul 2023
- Celltrion Group Merger Announcement in July & Oversold Post Disappointing Exclusion by OptumRX?28 Jun 2023
- Celltrion Inc (068270 KS): Turning Bullish As Biosimilar Revenue Rebounds & US Launches Imminent15 May 2023
- Celltrion (068270 KS): Disappointing 4Q22 Result; No Immediate Respite Is Seen03 Mar 2023
- Celltrion (068270 KS): Competition Makes US Approval of New Oncology Biosimilar Unappealing30 Sep 2022
x